Brensocatib external R&D expenses — R&D
Insmed Brensocatib external R&D expenses — R&D decreased by 19.4% to $18.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.5%, from $20.66M to $18.48M. Over 3 years (FY 2022 to FY 2025), Brensocatib external R&D expenses — R&D shows relatively stable performance with a -2.0% CAGR.
Analysis
How to read this metric
An increase typically reflects accelerated clinical trial enrollment or expanded development activities, while a decrease may indicate the completion of specific study phases or a strategic shift in resource allocation.
Detailed definition
This metric represents the direct external costs incurred for the clinical development and research activities specifica...
Peer comparison
Biopharmaceutical peers report similar program-specific R&D costs, often categorized as direct clinical development expenses or external research spending for pipeline assets.
insm_segment_brensocatib_external_r_d_expenses_research_and_developmentHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.63M | $25.63M | $25.63M | $25.63M | $27.14M | $27.14M | $27.14M | $27.14M | $19.52M | $37.81M | $17.29M | $23.96M | $20.66M | $33.56M | $19.36M | $22.94M | $18.48M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +5.9% | +0.0% | +0.0% | +0.0% | -28.1% | +93.7% | -54.3% | +38.6% | -13.8% | +62.4% | -42.3% | +18.5% | -19.4% |
| YoY Change | — | — | — | — | +5.9% | +5.9% | +5.9% | +5.9% | -28.1% | +39.3% | -36.3% | -11.7% | +5.9% | -11.2% | +12.0% | -4.2% | -10.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's brensocatib external r&d expenses — r&d?
- Insmed (INSM) reported brensocatib external r&d expenses — r&d of $18.48M in Q1 2026.
- How has Insmed's brensocatib external r&d expenses — r&d changed year-over-year?
- Insmed's brensocatib external r&d expenses — r&d decreased by 10.5% year-over-year, from $20.66M to $18.48M.
- What is the long-term trend for Insmed's brensocatib external r&d expenses — r&d?
- Over 3 years (2022 to 2025), Insmed's brensocatib external r&d expenses — r&d has grown at a -2.0% compound annual growth rate (CAGR), from $102.53M to $96.52M.
- What does brensocatib external r&d expenses — r&d mean?
- The amount of money spent on third-party services and clinical trials specifically for the Brensocatib drug program.